Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women. (PANNA)

  • End date
    Dec 16, 2025
  • participants needed
  • sponsor
    Radboud University Medical Center
Updated on 7 October 2022
antiretroviral agents
hiv antibody
HIV Vaccine
immune globulin
antibody test
hiv antibodies


Due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an HIV-infected pregnant woman. For the agents under study no or limited pharmacokinetic data during pregnancy are available. As the changes in pharmacokinetics during pregnancy are most prominent in the third trimester a pharmacokinetic curve will be recorded in the third trimester after attaining steady state.


The following agents will be studied:

Etravirine, Intelence, TMC125; Emtricitabine, Emtriva or FTC; Tenofovir, Viread, TDF; Atazanavir, Reyataz; Fosamprenavir, Telzir, FPV; Darunavir, Prezista, TMC114; Tipranavir, Aptivus, TPV; Indinavir, Crixivan; abacavir; raltegravir, Isentress; Enfuvirtide, Fuzeon; Maraviroc, Celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, TAF, darunavir/cobicistat; doravirine; bictegravir

Condition HIV Infections
Clinical Study IdentifierNCT00825929
SponsorRadboud University Medical Center
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

HIV-infected as documented by positive HIV antibody test and confirmed by Western Blot
Subject is at least 18 years of age at screening
Subject is able and willing to sign the Informed Consent Form prior to screening evaluations
Treated with an HAART regimen containing at least one agent which is mentioned in Appendix 1 of the protocol; this agent has been taken for at least 2 weeks before the day of first PK curve evaluation
Duration of pregnancy not longer than 33 weeks at the day of screening
Subject is able to adhere to food intake recommendations

Exclusion Criteria

Relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion
Inability to understand the nature and extent of the study and the procedures required
Presence of grade III/IV anemia (i.e. Hb <4.6 mmol/L or <7.4 g/dL)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note